Brief: Mannkind Says Afrezza Available To Eligible Patients For $35 Or Less Per Month
29/05/2026 17:33
BRIEF-Mannkind Says Afrezza Available To Eligible Patients For $35 Or Less Per Month May 29 (Reuters) - MannKind Corp MNKD.O:
MANNKIND ANNOUNCES FDA APPROVAL OF AFREZZA®, THE FIRST AND ONLY INHALED MEALTIME INSULIN FOR USE IN CHILDREN AND ADOLESCENTS AGED 6 AND OLDER LIVING WITH DIABETES
MANNKIND - AFREZZA AVAILABLE TO ELIGIBLE PATIENTS FOR $35 OR LESS PER MONTH
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children